{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:26:56Z","timestamp":1792837616523,"version":"4.5.0"},"reference-count":55,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n In 2021, more than 80\u202f000 US residents died from an opioid overdose. Public health intervention initiatives, such as the Helping to End Addiction Long-term (HEALing) Communities Study (HCS), are being launched with the goal of reducing opioid-related overdose deaths (OODs).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the change in the projected number of OODs under different scenarios of the duration of sustainment of interventions, compared with the status quo.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This decision analytical model simulated the opioid epidemic in the 4 states participating in the HCS (ie, Kentucky, Massachusetts, New York, and Ohio) from 2020 to 2026. Participants were a simulated population transitioning from opioid misuse to opioid use disorder (OUD), overdose, treatment, and relapse. The model was calibrated using 2015 to 2020 data from the National Survey on Drug Use and Health, the US Centers for Disease Control and Prevention, and other sources for each state. The model accounts for reduced initiation of medications for OUD (MOUDs) and increased OODs during the COVID-19 pandemic.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Increasing MOUD initiation by 2- or 5-fold, improving MOUD retention to the rates achieved in clinical trial settings, increasing naloxone distribution efforts, and furthering safe opioid prescribing. An initial 2-year duration of interventions was simulated, with potential sustainment for up to 3 additional years.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Projected reduction in number of OODs under different combinations and durations of sustainment of interventions.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Compared with the status quo, the estimated annual reduction in OODs at the end of the second year of interventions was 13% to 17% in Kentucky, 17% to 27% in Massachusetts, 15% to 22% in New York, and 15% to 22% in Ohio. Sustaining all interventions for an additional 3 years was estimated to reduce the annual number of OODs at the end of the fifth year by 18% to 27% in Kentucky, 28% to 46% in Massachusetts, 22% to 34% in New York, and 25% to 41% in Ohio. The longer the interventions were sustained, the better the outcomes; however, these positive gains would be washed out if interventions were not sustained.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this decision analytical model study of the opioid epidemic in 4 US states, sustained implementation of interventions, including increased delivery of MOUDs and naloxone supply, was found to be needed to reduce OODs and prevent deaths from increasing again.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.14925","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T11:31:50Z","timestamp":1686310310000},"page":"e2314925","source":"Crossref","is-referenced-by-count":47,"title":["Estimated Reductions in Opioid Overdose Deaths With Sustainment of Public Health Interventions in 4 US States"],"prefix":"10.1001","volume":"6","author":[{"given":"Jagpreet","family":"Chhatwal","sequence":"first","affiliation":[{"name":"Institute for Technology Assessment, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Institute for Technology Assessment, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiushi","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute for Technology Assessment, Massachusetts General Hospital, Boston"},{"name":"Harold and Inge Marcus Department of Industrial and Manufacturing Engineering, The Pennsylvania State University, University Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeti","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Institute for Technology Assessment, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Adee","sequence":"additional","affiliation":[{"name":"Institute for Technology Assessment, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Zarkin","sequence":"additional","affiliation":[{"name":"RTI International, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"LaRochelle","sequence":"additional","affiliation":[{"name":"Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"},{"name":"Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B.","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Institute for Technology Assessment, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Barbosa","sequence":"additional","affiliation":[{"name":"RTI International, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"issue":"3","key":"zoi230461r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3418","article-title":"Forecasted and observed drug overdose deaths in the US during the COVID-19 pandemic in 2020.","volume":"5","author":"Cartus","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi230461r4","first-page":"235","article-title":"Reducing fatal opioid overdose: prevention, treatment and harm reduction strategies.","volume":"88","author":"Hawk","year":"2015","journal-title":"Yale J Biol Med"},{"issue":"11","key":"zoi230461r5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.7326\/M17-3074","article-title":"Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review.","volume":"168","author":"Fink","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"zoi230461r6","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1111\/add.13860","article-title":"Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States.","volume":"112","author":"Moyo","year":"2017","journal-title":"Addiction"},{"issue":"7","key":"zoi230461r7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1377\/hlthaff.2015.1496","article-title":"Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates.","volume":"35","author":"Patrick","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"zoi230461r8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/add.v111.5","article-title":"Effectiveness of Scotland\u2019s National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison.","volume":"111","author":"Bird","year":"2016","journal-title":"Addiction"},{"key":"zoi230461r9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.drugalcdep.2018.07.017","article-title":"The changing landscape of naloxone availability in the United States, 2011-2017.","volume":"191","author":"Freeman","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"zoi230461r10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.drugalcdep.2017.05.001","article-title":"Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids\u2014conception and maturation.","volume":"178","author":"McDonald","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi230461r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi230461r13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.","volume":"95","author":"Samples","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"zoi230461r14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder.","volume":"177","author":"Williams","year":"2020","journal-title":"Am J Psychiatry"},{"key":"zoi230461r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108329","article-title":"Addressing opioid overdose deaths: the vision for the HEALing communities study.","volume":"217","author":"Chandler","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi230461r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108335","article-title":"The HEALing (Helping to End Addiction Long-term) Communities Study: protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices.","volume":"217","author":"HEALing Communities Study Consortium","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"zoi230461r17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2105\/AJPH.2018.304590","article-title":"Modeling health benefits and harms of public policy responses to the US opioid epidemic.","volume":"108","author":"Pitt","year":"2018","journal-title":"Am J Public Health"},{"issue":"11","key":"zoi230461r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.23677","article-title":"Modeling mitigation strategies to reduce opioid-related morbidity and mortality in the US.","volume":"3","author":"Ballreich","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"25","key":"zoi230461r19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm8147","article-title":"Reducing opioid use disorder and overdose deaths in the United States: a dynamic modeling analysis.","volume":"8","author":"Stringfellow","year":"2022","journal-title":"Sci Adv"},{"key":"zoi230461r20","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001153","article-title":"Long-term effects of increasing buprenorphine treatment seeking, duration, and capacity on opioid overdose fatalities: a model-based analysis.","author":"Stringfellow","year":"2023","journal-title":"J Addict Med"},{"issue":"1","key":"zoi230461r21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41398-020-0847-1","article-title":"America\u2019s opioid crisis: the need for an integrated public health approach.","volume":"10","author":"Blanco","year":"2020","journal-title":"Transl Psychiatry"},{"issue":"4","key":"zoi230461r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6147","article-title":"Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic.","volume":"4","author":"Currie","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi230461r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17029","article-title":"Changes in admissions to specialty addiction treatment facilities in California during the COVID-19 pandemic.","volume":"4","author":"Mark","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi230461r24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"2","key":"zoi230461r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7621","article-title":"Prevention of prescription opioid misuse and projected overdose deaths in the United States.","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"zoi230461r26","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"zoi230461r27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/SAR","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder.","volume":"9","author":"Ronquest","year":"2018","journal-title":"Subst Abuse Rehabil"},{"key":"zoi230461r28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.","volume":"85","author":"Morgan","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"zoi230461r29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review.","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis"},{"issue":"9","key":"zoi230461r30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi230461r32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction.","volume":"10","author":"Dugosh","year":"2016","journal-title":"J Addict Med"},{"issue":"11","key":"zoi230461r33","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00127-015-1088-0","article-title":"The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) waves 1 and 2: review and summary of findings.","volume":"50","author":"Hasin","year":"2015","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"12","key":"zoi230461r34","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.2105\/AJPH.2018.304673","article-title":"Estimated prevalence of opioid use disorder in Massachusetts, 2011-2015: a capture-recapture analysis.","volume":"108","author":"Barocas","year":"2018","journal-title":"Am J Public Health"},{"key":"zoi230461r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100052","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? using multiplier approaches to estimate prevalence for an unknown population size.","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"key":"zoi230461r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103392","article-title":"Changes in characteristics of drug overdose death trends during the COVID-19 pandemic.","volume":"98","author":"DiGennaro","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi230461r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.7112","article-title":"Trends in drug overdose mortality in Ohio during the first 7 months of the COVID-19 pandemic.","volume":"4","author":"Currie","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi230461r39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jama.2021.8012","article-title":"Mortality from drug overdoses, homicides, unintentional injuries, motor vehicle crashes, and suicides during the pandemic, March-August 2020.","volume":"326","author":"Faust","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"zoi230461r40","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2105\/AJPH.2021.306256","article-title":"COVID-19 and the drug overdose crisis: uncovering the deadliest months in the United States, January\u2013July 2020.","volume":"111","author":"Friedman","year":"2021","journal-title":"Am J Public Health"},{"key":"zoi230461r41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.annepidem.2022.11.007","article-title":"Estimating the impact of the COVID-19 pandemic on rising trends in drug overdose mortality in the United States, 2018-2021.","volume":"77","author":"Lee","year":"2023","journal-title":"Ann Epidemiol"},{"issue":"7","key":"zoi230461r44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/11314830-000000000-00000","article-title":"Calibration methods used in cancer simulation models and suggested reporting guidelines.","volume":"27","author":"Stout","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"zoi230461r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37259","article-title":"Projected estimates of opioid mortality after community-level interventions.","volume":"4","author":"Linas","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"23","key":"zoi230461r46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2115714119","article-title":"Modeling the evolution of the US opioid crisis for national policy development.","volume":"119","author":"Lim","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"zoi230461r47","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.jval.2020.03.015","article-title":"Economic evaluation of interventions to address opioid misuse: a systematic review of methods used in simulation modeling studies.","volume":"23","author":"Barbosa","year":"2020","journal-title":"Value Health"},{"key":"zoi230461r48","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: a rapid review.","volume":"35","author":"Mackey","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"2","key":"zoi230461r49","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10826084.2017.1363238","article-title":"Barriers to medications for addiction treatment: how stigma kills.","volume":"53","author":"Wakeman","year":"2018","journal-title":"Subst Use Misuse"},{"issue":"3","key":"zoi230461r50","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","article-title":"A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States.","volume":"46","author":"Lister","year":"2020","journal-title":"Am J Drug Alcohol Abuse"},{"key":"zoi230461r51","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugpo.2017.06.003","article-title":"US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations.","volume":"46","author":"Unick","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"6","key":"zoi230461r52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.amepre.2017.06.009","article-title":"Geographic variation in opioid and heroin involved drug poisoning mortality rates.","volume":"53","author":"Ruhm","year":"2017","journal-title":"Am J Prev Med"},{"issue":"6","key":"zoi230461r53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder.","volume":"2","author":"Haffajee","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi230461r54","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/1475-6773.12686","article-title":"Geographic disparities in availability of opioid use disorder treatment for Medicaid enrollees.","volume":"53","author":"Abraham","year":"2018","journal-title":"Health Serv Res"},{"key":"zoi230461r55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.drugpo.2018.04.011","article-title":"Opioid-related mortality in rural America: geographic heterogeneity and intervention strategies.","volume":"57","author":"Rigg","year":"2018","journal-title":"Int J Drug Policy"},{"key":"zoi230461r1","unstructured":"US Department of Health and Human Services. HHS Acting Secretary declares public health emergency to address national opioid crisis. October 26, 2017. Accessed August 7, 2022. https:\/\/www.hhs.gov\/about\/news\/2017\/10\/26\/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html"},{"key":"zoi230461r3","unstructured":"Ahmad? F, Rossen? L, Sutton? P. Provisional drug overdose death counts. National Center for Health Statistics. Accessed May 23, 2022. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi230461r12","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health. Accessed April 18, 2023. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt35325\/NSDUHFFRPDFWHTMLFiles2020\/2020NSDUHFFR1PDFW102121.pdf"},{"key":"zoi230461r31","unstructured":"US Department of Justice, Drug Enforcement Administration. Automated Reports and Consolidated Ordering System (ARCOS) retail drug summary reports. Accessed July 26, 2022. https:\/\/www.deadiversion.usdoj.gov\/arcos\/retail_drug_summary\/index.html"},{"key":"zoi230461r35","unstructured":"US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health: model-based prevalence estimates (50 states and the District of Columbia). Accessed July 26, 2022. https:\/\/www.samhsa.gov\/data\/nsduh\/state-reports-NSDUH-2020"},{"key":"zoi230461r42","unstructured":"US Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2019 on CDC WONDER online database. Accessed July 26, 2022. https:\/\/wonder.cdc.gov\/mcd-icd10.html"},{"key":"zoi230461r43","unstructured":"US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS). Accessed July 26, 2022. https:\/\/www.samhsa.gov\/data\/data-we-collect\/n-ssats-national-survey-substance-abuse-treatment-services"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2805808\/chhatwal_2023_oi_230461_1685637298.765.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T11:31:57Z","timestamp":1686310317000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2805808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14925","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}